|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 114.14 AUD | -0.64% |
|
+1.15% | -33.87% |
| 04:23am | CSL Says CHMP Recommends Revocation of TAVNEOS Marketing Authorization in Europe | MT |
| 06-26 | European Regulator Calls for Amgen's Tavneos to Have Authorization Revoked -- Update | DJ |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 37.98B | - | ||||
| 64.39B | |||||
| 56.12B | |||||
| 40.54B | |||||
| 31.89B | |||||
| 26.69B | - |
- Stock Market
- Stocks
- CSL Stock
- Charts CSL Limited
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
